Shu Li

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

76-Week Results, Immunology, Clinical Trials +7

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.3K citations

Immunology, Clinical Trials, Clinical Dermatology +7

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Kristian Reich, Frank O. Nestlé, Kim Papp et al. · The Lancet · 2005 · 1K citations

Infliximab Induction, Systemic Treatment, Phase Iii +7

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof et al. · New England Journal of Medicine · 2010 · 845 citations

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 838 citations · Full text